3 Growth Stocks You Can Buy Right Now with Less Than $100

Capital of less than $100 is enough to buy one of these three promising growth stocks that don’t belong to the technology sector.

| More on:
Growing plant shoots on coins

Image source: Getty Images

Growth investors have exciting prospects to choose from, not in the technology sector but in healthcare, energy, and mining. BELLUS (TSX:BLU), Peyto Exploration & Development (TSX:PEY), and Perseus Mining Limited (TSX:PRU) have visible growth potential, and with less than $100 capital, you can buy one or all right now.

Promising trial results

Healthcare is the worst-performing sector in 2022, although BELLUS outperforms the broader market. At $11.60 per share, this biotech stock is up 14.06% year-to-date versus the TSX’s -7.90% year-to-date loss.

This $1.45 billion clinical-stage biotechnology company is developing BLU-5937, a highly selective P2X3 antagonist for refractory chronic cough (RCC). While biotech stocks are speculative, if not risky, the Phase 2b SOOTHE trial of BELLUS’ lead drug candidate showed positive topline results.

Management plans to initiate Phase 3 registration trials of BLU-5937 this quarter. Like most biotech firms, BELLUS still needs to make money. However, profits should pour in if BLU-5937 obtains FDA approval and makes it to the market.

Its President and CEO, Roberto Bellini, said BELLUS commits to bringing BLU-5937 to patients burdened by RCC. He adds that in Q2 2022, management has successfully identified a clear regulatory path to potential approval, and it should bring BELLUS closer to making its primary goal a reality.

Market analysts’ high price target for BLU is $28.31, or a potential 144% climb from its current share price.

Capital gains + dividends

For the first time since the launch of the flagship program for growth stocks in 2019, oil & gas companies dominated the 2022 TSX30 List. Peyto is one of 14 energy constituents that joined the pool of 30 top-performing stocks and ranked 17th in this year’s edition.

The $2.29 billion company explores and develops unconventional natural gas in Alberta’s Deep Basin. Its CEO, Darren Gee, said Peyto realized significant gains in revenues and cash flows in 2022 due to the relatively stable and high drilling rig utilizations, plus favourable commodity prices.

In Q2 2022, revenue and free funds flow increased 166% and 290% to $398.64 million and $97.81 million versus Q2 2021. Peyto’s earnings also soared 641% year-over-year to $94.54 million. At $13.49 per share, current investors enjoy a 48.8% year-to-date gain on top of the juicy 4.5% dividend yield.

Record fiscal 2022

Perseus is a 2022 TSX30 winner like Peyto. The mining stock is absurdly cheap at $1.65 per share, although the year-to-date gain is +12.43%. In 3.01 years, the overall return is 110.93%, which translates to a 28.19% compound annual growth rate (CAGR).

The $2.25 billion gold producer from Africa had an impressive fiscal 2022 due to strong operating performance at all levels of the business. In the 12 months ended June 30, 2022, revenue, net cash inflows, and profit increased 66%, 73%, and 101% year-over-year to $1.12 billion, $522.9 million, and $279.9 million, respectively.

Perseus’ record performance in all key metrics prompted the declaration of a bonus dividend ($0.79) in addition to the regular dividend ($1.64) for the year. The forward annual dividend yield is 2.11%.

Investment thesis

The healthcare stock will likely reap the rewards of success with its lead drug candidate, while the pair of TSX30 winners should extend their upward momentum in 2023.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Dividend Stocks

Dividend Stocks

10 Years From Now, You’ll Be Glad You Bought These Magnificent TSX Dividend Stocks

The TSX is lucrative to buy these magnificent dividend stocks in bulk and be proud of this decision 10 years…

Read more »

calculate and analyze stock
Dividend Stocks

4 Fabulous Dividend Stocks to Buy in July

Are you looking for long-term income? These four dividend stocks should not only provide you with value in July but…

Read more »

financial freedom sign
Dividend Stocks

5 Steps to Financial Freedom for Canadian Millennials

Follow these steps and nothing can stop Canadian millennials from achieving their early retirement dreams.

Read more »

Investor wonders if it's safe to buy stocks now
Dividend Stocks

We’re Only Getting Older: A Top TSX Stock That Benefits From an Aging Population

For a bet on the aging population, consider this small-cap stock with growth potential.

Read more »

Growing plant shoots on coins
Dividend Stocks

Yield Today, Growth Tomorrow: 3 Stocks to Keep Building Your Wealth

For investors seeking yield today and growth tomorrow, these top Canadian dividend stocks are certainly worth considering right now.

Read more »

Payday ringed on a calendar
Dividend Stocks

This 10.72% Dividend Stock Pays Cash Every Month

This dividend stock remains a consistent, defensive dividend producer that will give up over 10% in income each and every…

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Investors: 2 Standout Domestic Stocks With 7% Yields

These top dividend-growth stocks look oversold.

Read more »

Dividend Stocks

2 Dividend Stocks to Double Up on Right Now

Despite their recent declines, the long-term growth outlook of these two top dividend stocks remains strong, which could help their…

Read more »